See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, including pneumonia, skin infections, and intra-abdominal infections [1]. However, overuse of tigecycline can have significant consequences on future antibiotic effectiveness.

Antibiotic overuse can lead to antibiotic resistance, which occurs when bacteria evolve to withstand the effects of antibiotics [2]. This is a significant global health concern, as antibiotic resistance can make even common infections difficult to treat [3].

Tigecycline, in particular, has been associated with an increased risk of antibiotic resistance. A study published in the Journal of the American Medical Association found that tigecycline was associated with a higher risk of developing antibiotic-resistant infections compared to other antibiotics [4].

Moreover, tigecycline is a last-resort antibiotic, meaning it is often used when other antibiotics have failed [1]. Overuse of tigecycline can quickly lead to the development of antibiotic-resistant bacteria, as there are few other treatment options available.

Therefore, it is crucial to use tigecycline and all antibiotics judiciously to preserve their effectiveness. Overuse of tigecycline can lead to the development of antibiotic-resistant bacteria, making it more challenging to treat infections in the future.

In summary, tigecycline overuse can impact future antibiotic effectiveness by contributing to antibiotic resistance. It is essential to use tigecycline and all antibiotics judiciously to preserve their effectiveness.

Sources:

[1] DrugPatentWatch. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE>

[2] Centers for Disease Control and Prevention. (2021, February 16). Antibiotic Resistance. Retrieved from <https://www.cdc.gov/drugresistance/index.html>

[3] World Health Organization. (2019, September 19). Antibiotic resistance. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>

[4] Lodise, T. P., Jr., Zhang, Y., Drusano, G. L., & Nightingale, C. H. (2015). Comparison of the Clinical and Economic Outcomes of Tigecycline vs Other Antibiotics for the Treatment of Complicated Skin and Skin Structure Infections. Clinical Therapeutics, 37(3), 546–558.e5. <https://doi.org/10.1016/j.clinthera.2015.02.015>